retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Need a REST
link only shows philex symbol
HEARD THIS WHERE??????????????HA HA
Thank you
How do you follow PXP
its a piece of s**t.period. don't get sucked in
why?
Say What?????????????
DITTO
Which WAY???????????
Now we have remnants of two one million share sell orders.
All I know is that all four one million share sell orders were and are thru Cantor Fitz
Doesn't happen often,but happen.
Cause sellers BACK
Nothing is chump change,it's all too real
Looks like Cantor back with another 1 mill sell order.Lets see if it goes like last two.
.005 It went
.005 It went
.005 Will it GO or Grow
nothing in a week,pos
No the 2,500,000 @ .0013
A new buyer?????
How does one follow pxp
On bottom left click on global nation
.005 and .007
Two one million share sell orders!!!
Or thinks they know something
What just happened??
BOYS.KEEP IT CIVIL
THAT IS ENOUGH GUYS!!!!!!!!!!!
No one seems to care
WOW.Insider buy 50,000 @ 7.First in a while
Tax loss selling
Nice to see NO tax selling!!!!
HAPPY HOLIDAYS TO ALL
HAPPY HOLIDAYS TO ALL
This could be big
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and LipimetiX Development, Inc., the Company's drug development joint venture ("JV") announced today that the JV's lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.
A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/065505f4-bc99-4efc-b76d-b7d16c876ed3
Dennis I. Goldberg, PhD, President and CEO of LipimetiX Development, Inc. stated "AEM-28-14 has shown clinically-relevant levels of cholesterol reduction in multiple validated preclinical models and may be the most powerful lipid reduction agent yet discovered. Primate models are often predictive of a molecule's therapeutic performance in humans. Accordingly, we see the LDLc reduction in this primate model as consistent with the benefits that we hope to deliver to Homozygous Familial Hypercholesterolemia (HoFH) patients...powerful cholesterol lowering combined with duration of effect."
The JV's development goals are to conduct Phase 1a, 1b, and 2a human clinical trials with AEM-28-14 to show an acceptable safety profile and cholesterol reduction efficacy in HoFH, an orphan genetic disease characterized by extremely high LDLc due to inherited defects in the LDL receptor pathway from both parents. The hypercholesterolemia associated with HoFH is difficult to treat since it is refractory to drugs and biologics, such as statins and PCSK9 inhibitors, that increase the expression and functionality of the LDL receptor in normal patients.
Chimeric Apolipoprotein E Mimetic Peptides
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride-rich lipoproteins to specific receptors in the liver, decreasing these levels in the blood. Defective metabolism of cholesterol and triglyceride-rich lipoprotein remnants plays an important role in the development of diseases of the coronary, cerebral and peripheral arteries often leading to heart attack and stroke.
The University of Alabama at Birmingham ("UAB") scientists patented the first chimeric Apo E mimetic peptide in 1999, reducing the 299 amino acid native Apo E into a 28 amino acid, dual domain peptide that can be delivered therapeutically. One domain inserts into a lipoprotein surface and the second domain binds to the Apo E receptors in the liver. In 2010, our JV's founding scientist, Dr. Dennis Goldberg, obtained worldwide right to patents for Apo E mimetic peptides from the UAB Research Foundation ("UABRF"). The JV has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and its analogs.
The JV has continued research in to a new generation of chimeric Apo E peptides and has discovered AEM-28-14, resulting in a USPTO and PCT patent filing in 2015 supporting claims for a broad domain of Apo E mimetic peptides. AEM-28-14 was found to be more potent (as tested in multiple
Sounds like a good chance of approval
ODD action Friday